Healthcare / Diagnostics & ResearchShanghai
$13.00
+0.45 (+3.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $409.8M · quality 30.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.8B
P/E
N/A
•EV/EBITDA
75.6x
↑ROE
-14.5%
↓Gross Margin
21.4%
↓Debt/Equity
1.79
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.6%
FCF CAGR
—
FCF margin
5.5%
FCF / Net income
-0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.00B · net income $-548.4M · FCF $386.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.00B | $7.00B | $8.31B | $9.15B | $10.49B |
| Net Income | $-548.4M | $-548.4M | $55.3M | $273.3M | $417.7M |
| EBITDA | $179.8M | $179.8M | $1.05B | $1.36B | $1.52B |
| EPS | -0.91 | -0.91 | 0.09 | 0.47 | 0.70 |
| Gross Margin | 21.4% | 21.4% | 25.4% | 26.6% | 28.0% |
| Operating Margin | 2.9% | 2.9% | 8.0% | 9.2% | 11.6% |
| Net Margin | -7.8% | -7.8% | 0.7% | 3.0% | 4.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.79 | 1.79 | 1.59 | 1.56 | 1.77 |
| Current Ratio | 1.08 | 1.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $386.7M | $386.7M | $417.8M | $409.8M | $-701.0M |
| Returns | |||||
| ROE | -14.5% | -14.5% | 1.3% | 6.4% | 10.7% |
| Valuation | |||||
| P/E | — | — | 162.00 | 39.77 | 14.74 |
| EV/EBITDA | 75.60 | 75.60 | 13.93 | 12.08 | 7.90 |
| P/B | 2.07 | 2.07 | 2.06 | 2.54 | 1.58 |
| Growth & Yield | |||||
| Revenue Growth | -15.8% | -15.8% | -9.1% | -12.8% | — |
| EPS Growth | -1111.1% | -1111.1% | -80.9% | -32.9% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.09 → -0.91
Residual
-26.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.